Uganda is set to introduce a groundbreaking HIV prevention tool following successful global research that includes significant contributions from Ugandan scientists. The Uganda AIDS Commission has announced that Lenacapavir, a six-monthly injectable medication for pre-exposure prophylaxis (PrEP), has been proven to offer 100% protection to HIV-negative individuals.
The announcement follows the approval of Lenacapavir by the United States Food and Drug Administration (FDA). Uganda is now preparing to make the drug available after fulfilling key regulatory and policy requirements.
The Ministry of Health will collaborate with stakeholders to ensure the National Drug Authority evaluates and licenses Lenacapavir for local use. National HIV prevention guidelines will be updated to reflect its integration.
Healthcare providers will undergo training to gain the knowledge and skills necessary to prescribe and monitor Lenacapavir. The drug will be added to Uganda’s essential drugs list, and new data collection tools will be introduced to help track client usage and ensure accountability.
Once fully integrated, Lenacapavir will expand HIV prevention options in Uganda, particularly for individuals at high risk of infection. While preparations are underway, the country will continue offering oral PrEP at designated facilities. Uganda has also incorporated Cabotegravir, another long-acting injectable PrEP administered every two months, into its national prevention strategy.
The Uganda AIDS Commission reaffirmed its commitment to ending AIDS as a public health threat by 2030 through innovative and science-backed interventions.